Señales en vivo de IMGN | Maximiza tus Ganancias con Getagraph.com

VENDER 116753 min ago

@ $31.23

Emitido: 8 feb 2024 @ 09:30

Retorno: 0.02%

Señal anterior: feb 7 - 15:55

Señal anterior: Comprar

Retorno: 5.67 %

Live Chart Being Loaded With Signals

Commentary (9 feb 2024 @ 15:58):

Stats
Volumen de hoy	19.31M
Volumen promedio	8.29M
Capitalización de mercado	8.73B
EPS	$0 ( 2024-04-26 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-111.55
ATR14	$0.306 (0.98%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-12	Mitchell Dean J	Sell	103 000	Common Stock
2024-02-12	Mitchell Dean J	Sell	13 090	Restricted Stock Unit
2024-02-12	Mitchell Dean J	Sell	142 667	Deferred Share Unit
2024-02-12	Mitchell Dean J	Sell	10 000	Stock Option (Right to Buy)
2024-02-12	Mitchell Dean J	Sell	10 000	Stock Option (Right to Buy)

INSIDER POWER
-100.00
Last 100 transactions
Buy: 0 \| Sell: 8 781 240

Volumen Correlación

Largo: 0.24 (neutral)

Corto: 0.25 (neutral)

Signal:(82.516) Neutral

ImmunoGen Inc Correlación

10 Correlaciones Más Positivas
HOL	0.945
IRBT	0.93
SLNG	0.929
RTPY	0.927
KBSF	0.926
LGMK	0.92
RPID	0.919
FIBK	0.917
GBCI	0.917
LYEL	0.917

10 Correlaciones Más Negativas
AEAE	-0.941
ENTF	-0.941
CCTS	-0.941
HORI	-0.939
GHIX	-0.938
FIAC	-0.938
XPAX	-0.938
NECB	-0.936
ADAL	-0.935
ACAB	-0.935

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

ImmunoGen Inc Correlación - Moneda/Commodity

-0.22
( neutral )

0.51
( weak )

0.55
( weak )

-0.04
( neutral )

0.31
( neutral )

0.26
( neutral )

ImmunoGen Inc Finanzas

Annual	2022
Ingresos:	$108.78M
Beneficio Bruto:	$108.61M (99.84 %)
EPS:	$-0.880

FY	2022
Ingresos:	$108.78M
Beneficio Bruto:	$108.61M (99.84 %)
EPS:	$-0.880

FY	2022
Ingresos:	$108.78M
Beneficio Bruto:	$108.61M (99.84 %)
EPS:	$-0.880

FY	2020
Ingresos:	$132.30M
Beneficio Bruto:	$17.71M (13.38 %)
EPS:	$-0.250

Financial Reports:

No articles found.

ImmunoGen Inc

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.